PortalPublikationenAssays for prostate cancer: changing the screening paradigm?

Assays for prostate cancer: changing the screening paradigm?

Standard

Assays for prostate cancer: changing the screening paradigm? / Hansen, Jens; Rink, Michael; Graefen, Markus; Shariat, Shahrokh; Chun, Felix K-H.

in: MOL DIAGN THER, Jahrgang 17, Nr. 1, 01.02.2013, S. 1-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hansen, J, Rink, M, Graefen, M, Shariat, S & Chun, FK-H 2013, 'Assays for prostate cancer: changing the screening paradigm?', MOL DIAGN THER, Jg. 17, Nr. 1, S. 1-8. https://doi.org/10.1007/s40291-013-0014-y

APA

Hansen, J., Rink, M., Graefen, M., Shariat, S., & Chun, F. K-H. (2013). Assays for prostate cancer: changing the screening paradigm? MOL DIAGN THER, 17(1), 1-8. https://doi.org/10.1007/s40291-013-0014-y

Vancouver

Hansen J, Rink M, Graefen M, Shariat S, Chun FK-H. Assays for prostate cancer: changing the screening paradigm? MOL DIAGN THER. 2013 Feb 1;17(1):1-8. https://doi.org/10.1007/s40291-013-0014-y

Bibtex

@article{d98d617ccbd5431684d1fededcc38c0f,
title = "Assays for prostate cancer: changing the screening paradigm?",
abstract = "Prostate cancer (PCa) screening and detection have changed dramatically since the introduction of serum prostate-specific antigen (PSA) testing. Despite the resulting improvement in early PCa detection and stage migration, in clinical practice the use of PSA testing may cause overdetection and ultimately overtreatment. As a consequence, novel biomarkers are needed to increase the specificity of PCa detection. The aim of this article is to present an overview of novel blood- and urine-based biomarkers that may optimize PCa detection, with improved identification of patients with significant PCa and avoidance of unnecessary prostate biopsies. A systematic and comprehensive PubMed search was performed using the MeSH search terms 'prostate cancer', 'biomarker', 'marker', and 'detection'. Results were restricted to the English language. Several blood- and urine-based biomarkers have the potential to improve prediction of the presence and/or significance of PCa. Ideally, biomarkers should be used in combination within multivariate models, leading to superior accuracy for prediction of any PCa or clinically significant PCa, compared with the use of a single marker.",
keywords = "Annexin A3, Antigens, Neoplasm, Biopsy, DNA, Early Detection of Cancer, Humans, Male, Plasminogen Activators, Prostate-Specific Antigen, Prostatic Neoplasms, Sensitivity and Specificity, Serine Endopeptidases, Tumor Markers, Biological",
author = "Jens Hansen and Michael Rink and Markus Graefen and Shahrokh Shariat and Chun, {Felix K-H}",
year = "2013",
month = feb,
day = "1",
doi = "10.1007/s40291-013-0014-y",
language = "English",
volume = "17",
pages = "1--8",
journal = "MOL DIAGN THER",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Assays for prostate cancer: changing the screening paradigm?

AU - Hansen, Jens

AU - Rink, Michael

AU - Graefen, Markus

AU - Shariat, Shahrokh

AU - Chun, Felix K-H

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Prostate cancer (PCa) screening and detection have changed dramatically since the introduction of serum prostate-specific antigen (PSA) testing. Despite the resulting improvement in early PCa detection and stage migration, in clinical practice the use of PSA testing may cause overdetection and ultimately overtreatment. As a consequence, novel biomarkers are needed to increase the specificity of PCa detection. The aim of this article is to present an overview of novel blood- and urine-based biomarkers that may optimize PCa detection, with improved identification of patients with significant PCa and avoidance of unnecessary prostate biopsies. A systematic and comprehensive PubMed search was performed using the MeSH search terms 'prostate cancer', 'biomarker', 'marker', and 'detection'. Results were restricted to the English language. Several blood- and urine-based biomarkers have the potential to improve prediction of the presence and/or significance of PCa. Ideally, biomarkers should be used in combination within multivariate models, leading to superior accuracy for prediction of any PCa or clinically significant PCa, compared with the use of a single marker.

AB - Prostate cancer (PCa) screening and detection have changed dramatically since the introduction of serum prostate-specific antigen (PSA) testing. Despite the resulting improvement in early PCa detection and stage migration, in clinical practice the use of PSA testing may cause overdetection and ultimately overtreatment. As a consequence, novel biomarkers are needed to increase the specificity of PCa detection. The aim of this article is to present an overview of novel blood- and urine-based biomarkers that may optimize PCa detection, with improved identification of patients with significant PCa and avoidance of unnecessary prostate biopsies. A systematic and comprehensive PubMed search was performed using the MeSH search terms 'prostate cancer', 'biomarker', 'marker', and 'detection'. Results were restricted to the English language. Several blood- and urine-based biomarkers have the potential to improve prediction of the presence and/or significance of PCa. Ideally, biomarkers should be used in combination within multivariate models, leading to superior accuracy for prediction of any PCa or clinically significant PCa, compared with the use of a single marker.

KW - Annexin A3

KW - Antigens, Neoplasm

KW - Biopsy

KW - DNA

KW - Early Detection of Cancer

KW - Humans

KW - Male

KW - Plasminogen Activators

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Sensitivity and Specificity

KW - Serine Endopeptidases

KW - Tumor Markers, Biological

U2 - 10.1007/s40291-013-0014-y

DO - 10.1007/s40291-013-0014-y

M3 - SCORING: Journal article

C2 - 23355098

VL - 17

SP - 1

EP - 8

JO - MOL DIAGN THER

JF - MOL DIAGN THER

SN - 1177-1062

IS - 1

ER -